Eplerenone crystalline form

Abstract

The present invention provides a novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone having relatively hich physical stability at normal temperatures of storage and use. The present invention provides Pharmaceutical compositionscomprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form L eplerenone and for preparing compositions comprising Form L eplerenone. The present invention a method for prophylaxis and / or treatment of an aldosterone-mediated condition or disorder, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form L eplerenone.

Description

field of invention

[0001] The present invention relates to pharmaceutically active agents which are aldosterone receptor antagonists, more particularly the present invention relates to the aldosterone receptor antagonist eplerenone. In particular, the present invention relates to a new crystalline form of eplerenone, a method for preparing the crystalline form, a pharmaceutical composition comprising the crystalline form, the use of the crystalline form for the treatment and / or prevention of aldosterone-mediated disorders and / or diseases, including Process for a plethora of related disorders and diseases such as hypertension, and the use of the crystalline form for the preparation of medicaments. Background of the invention

[0002] The compound 9,11-epoxy-17-hydroxy-3-oxopregna-4-ene-7,21-dicarboxylate monohydrogen ester, γ-lactone, having structure (I) and called eplerenone was reported for the first time In US Pat. No. 4,559,332 to Grob et al., t...

Examples

Embodiment 1

[0244] The following examples describe in detail the preparation of various solid state forms of eplerenone described herein. These detailed descriptions are within the scope of the invention and are illustrative of the invention and are not intended to limit the scope of the invention in any way. All percentages are by weight unless otherwise indicated. The eplerenone starting material used in each of the following examples was prepared according to Scheme 1 of the above-cited International Patent Publication WO 98 / 25948. Embodiment 1: prepare butanone compound by high-purity eplerenone raw material and prepare by this solvate Eplerenone Crystalline Form L

[0245] A. Preparation of Butanone Compounds

[0246] Under magnetic stirring at 900 rpm, 437 mg of high-purity eplerenone (purity > 99%, and the total content of diepoxide and 11,12-epoxide < 0.2%) was dissolved by heating to boiling on a hot plate. In 10ml butanone. Under continuous magnetic stirring, the result...

Embodiment 2

[0249] According to the same method as in Example 1, the following solvents were used instead of butanone to prepare additional solvates: n-propanol, 2-pentanone, acetic acid, acetone, butyl acetate, chloroform, ethanol, isobutanol , isobutyl acetate, isopropanol, methyl acetate, ethyl propionate, n-butanol, n-octanol, propyl acetate, propylene glycol, tert-butanol, tetrahydrofuran, and toluene. Example 3: Preparation of Butanone Compounds by Vapor Diffusion Growth

Embodiment 3

[0250] A stock solution was formed by dissolving 400 mg of eplerenone (>99.9% purity) in 20 ml of methyl ethyl ketone by warming on a hot plate. 8 ml of this stock solution was diluted to 10 ml with butanone, and the resulting solution was referred to as an 80% diluted sample. 4 ml of this stock solution was diluted to 10 ml with butanone (40% diluted sample). 2 ml of this stock solution was diluted to 10 ml with butanone (20% diluted sample). Each diluted sample in a 20 ml scintillation vial was transferred to a dry jar containing a small amount of hexane as an anti-solvent. The dry jar was sealed and the hexane vapor was allowed to diffuse into the butanone solution. Crystals of eplerenone butanate grew in 80% of the diluted samples within 24 hours. Embodiment 4: Preparation of eplerenone solvate crystals by rotary evaporator

field of invention

[0001] The present invention relates to pharmaceutically active agents which are aldosterone receptor antagonists, more particularly the present invention relates to the aldosterone receptor antagonist eplerenone. In particular, the present invention relates to a new crystalline form of eplerenone, a method for preparing the crystalline form, a pharmaceutical composition comprising the crystalline form, the use of the crystalline form for the treatment and / or prevention of aldosterone-mediated disorders and / or diseases, including Process for a plethora of related disorders and diseases such as hypertension, and the use of the crystalline form for the preparation of medicaments. Background of the invention

[0002] The compound 9,11-epoxy-17-hydroxy-3-oxopregna-4-ene-7,21-dicarboxylate monohydrogen ester, γ-lactone, having structure (I) and called eplerenone was reported for the first time In US Pat. No. 4,559,332 to Grob et al., t...

Examples

Embodiment 1

[0244] The following examples describe in detail the preparation of various solid state forms of eplerenone described herein. These detailed descriptions are within the scope of the invention and are illustrative of the invention and are not intended to limit the scope of the invention in any way. All percentages are by weight unless otherwise indicated. The eplerenone starting material used in each of the following examples was prepared according to Scheme 1 of the above-cited International Patent Publication WO 98 / 25948. Embodiment 1: prepare butanone compound by high-purity eplerenone raw material and prepare by this solvate Eplerenone Crystalline Form L

[0245] A. Preparation of Butanone Compounds

[0246] Under magnetic stirring at 900 rpm, 437 mg of high-purity eplerenone (purity > 99%, and the total content of diepoxide and 11,12-epoxide < 0.2%) was dissolved by heating to boiling on a hot plate. In 10ml butanone. Under continuous magnetic stirring, the result...

Embodiment 2

[0249] According to the same method as in Example 1, the following solvents were used instead of butanone to prepare additional solvates: n-propanol, 2-pentanone, acetic acid, acetone, butyl acetate, chloroform, ethanol, isobutanol , isobutyl acetate, isopropanol, methyl acetate, ethyl propionate, n-butanol, n-octanol, propyl acetate, propylene glycol, tert-butanol, tetrahydrofuran, and toluene. Example 3: Preparation of Butanone Compounds by Vapor Diffusion Growth

Embodiment 3

[0250] A stock solution was formed by dissolving 400 mg of eplerenone (>99.9% purity) in 20 ml of methyl ethyl ketone by warming on a hot plate. 8 ml of this stock solution was diluted to 10 ml with butanone, and the resulting solution was referred to as an 80% diluted sample. 4 ml of this stock solution was diluted to 10 ml with butanone (40% diluted sample). 2 ml of this stock solution was diluted to 10 ml with butanone (20% diluted sample). Each diluted sample in a 20 ml scintillation vial was transferred to a dry jar containing a small amount of hexane as an anti-solvent. The dry jar was sealed and the hexane vapor was allowed to diffuse into the butanone solution. Crystals of eplerenone butanate grew in 80% of the diluted samples within 24 hours. Embodiment 4: Preparation of eplerenone solvate crystals by rotary evaporator

Images